The PCN recommends Aflibercept as a treatment option for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE TA409 (28th September 2016). Aflibercept is a payment by results excluded drug which will be considered RED on the traffic light system.
The PCN recommends aflibercept (Eylea®) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion in line with NICE TA 305 (February 2014) and the NICE FAQ document relating to local formularies (link to document below). Aflibercept will be considered RED on the traffic light system
